DUBLIN, Nov. 10, 2023 /PRNewswire/ — The “Global Non-Alcoholic Steatohepatitis Market (by Drug Type, Application Type, Distribution Type, & Region): Insights and Forecast with Potential Impact of COVID-19 (2022-2027)” report has been added to ResearchAndMarkets.com’s offering.
The global Non-Alcoholic Steatohepatitis (NASH) market is poised to achieve a market value of US$2.71 billion by 2023, demonstrating an impressive Compound Annual Growth Rate (CAGR) of 53.49% over the projected period. NASH is an inflammatory liver disease characterized by fat accumulation, hepatocellular ballooning, and inflammation, primarily affecting non-alcoholics or those who consume minimal alcohol.
NASH, often referred to as “Silent Liver Disease,” is a liver disorder caused by long-term alcohol abuse but mainly impacts non-alcoholics. It is the second stage of Non-Alcoholic Fatty Liver Disease (NAFLD), marked by liver inflammation and cell damage. Factors such as increased investment in medical infrastructure, rising consumption of processed foods, a focus on drug development, and non-invasive diagnostic procedures contribute to market growth.
The global NASH market is segmented as follows:
- Drug Type: The market is divided into five segments: Vitamin E & Pioglitazone, Ocaliva, Elafibranor, Selonsertib & Cenicriviroc, and Others. The Vitamin E & Pioglitazone segment holds the largest market share, given their effectiveness in NASH treatment. Elafibranor is the fastest-growing segment, supported by positive clinical trial outcomes and its ability to reduce liver fat and improve NASH-related conditions.
- Application Type: Segmented into treatment and diagnosis, the NASH treatment market is the largest and fastest-growing segment due to the increasing prevalence of NASH and the expected launch of new pipeline drugs.
- Distribution Type: The market includes retail pharmacies, online pharmacies, and hospital pharmacies. Retail pharmacies lead the market due to their widespread presence, patient-centric services, convenient locations, and comprehensive drug portfolios.
The global NASH market is categorized into North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. North America dominates the market due to the rising prevalence of chronic diseases, increased healthcare spending, and the presence of major NASH players. Asia Pacific is expected to experience the fastest growth, driven by NASH’s increasing prevalence, advancing healthcare infrastructure, and international investments in countries like China and India. China holds the largest share in the Asia Pacific NASH market.
Drivers: Rising Prevalence of NASH
The increasing incidence of NASH, a chronic inflammatory liver disease, fuels the demand for NASH therapeutics, diagnostic tools, and treatment practices. Left untreated, NASH can progress to cirrhosis and liver cancer, along with an elevated risk of heart disease and stroke, making it crucial to address this condition.
Challenges: Lack of Low-Cost and Definitive Diagnostic Methods
NASH diagnosis currently relies on time-consuming and invasive methods such as liver biopsy, which is costly and associated with risks. The absence of conclusive diagnostic methods and low diagnosis rates, with only around 20% of cases being diagnosed, hinders market growth.
Trend: Integration of Artificial Intelligence (AI)
Medical professionals are utilizing bioinformatics and AI to gain a better understanding of NASH, develop personalized medicine strategies, and improve disease management. AI aids in disease mechanism comprehension, biomarker identification, disease progression/regression tracking, and prediction of drug responders, enhancing NASH therapeutics demand.
The COVID-19 pandemic, characterized by lockdowns, sedentary lifestyles, increased processed food consumption, and reduced exercise, raised the risk factors for NASH. It also led to an upsurge in cardiovascular and metabolic risk factors and the emergence of new chronic conditions, elevating NAFLD and NASH risks. As a result, there was an increased demand for NASH treatment, diagnostic tools, and emerging drugs, positively impacting the market.
The global NASH market is characterized by consolidation, with key players including Siemens Healthineers AG, Novartis AG, Intercept Pharmaceuticals, Inc., AstraZeneca PLC, Galectin Therapeutics Inc., Madrigal Pharmaceuticals, Inc., Inventiva S.A., GENFIT S.A., Galmed Pharmaceuticals Ltd., Prometheus Laboratories Inc., BioPredictive, ONE WAY LIVER, S.L., and Cirius Therapeutics.
Top Impacting Factors
- Rising prevalence of Non-Alcoholic Steatohepatitis (NASH)
- Rising Cases of Associated Chronic Diseases
- Rising adoption of Sedentary Lifestyle
- Rising Health Awareness
- Absence of Low Cost and Definitive Diagnostic Methods
- Regulatory Compliance
- Increasing Integration of Artificial Intelligence (AI)
- Increased Promotion of Pipeline Drugs
- Increasing Investment on Research and Development (R&D)
For more information about this report visit https://www.researchandmarkets.com/r/y92e0x
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
The content is by PR Newswire. Headlines of Today Media is not responsible for the content provided or any links related to this content. Headlines of Today Media is not responsible for the correctness, topicality or the quality of the content.